Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Xencor Inc
(NQ:
XNCR
)
21.27
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Xencor Inc
< Previous
1
2
3
4
5
6
Next >
Xencor Reports First Quarter 2022 Financial Results
May 05, 2022
From
Xencor, Inc.
Via
Business Wire
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
May 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Earnings Scheduled For May 5, 2022
May 05, 2022
Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
Via
Benzinga
Xencor: Q4 Earnings Insights
February 23, 2022
Xencor (NASDAQ:XNCR) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Xencor...
Via
Benzinga
Xencor's Earnings Outlook
May 04, 2022
Xencor (NASDAQ:XNCR) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Xencor will report...
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
May 04, 2022
During Wednesday's trading, 435 companies set new 52-week lows.
Via
Benzinga
Xencor to Host First Quarter 2022 Financial Results Webcast and Conference Call on May 5, 2022
April 28, 2022
From
Xencor, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Monday
April 18, 2022
On Monday, 466 companies hit new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was...
Via
Benzinga
Xencor Presents Data from Multiple Preclinical XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022
April 08, 2022
From
Xencor, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Tuesday
March 15, 2022
During Tuesday's session, 454 stocks hit new 52-week lows. Intriguing Points From Today's 52-Week Lows: Taiwan Semiconductor (NYSE:TSM) was the largest company by...
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
March 08, 2022
Tuesday's session saw 729 companies set new 52-week lows. Areas of Interest About Today's 52-Week Lows: Amazon.com (NASDAQ:AMZN) was the largest firm on a...
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
March 07, 2022
On Monday, 524 stocks hit new 52-week lows. Areas of Interest About Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Taiwan...
Via
Benzinga
Xencor Reports Fourth Quarter and Full Year 2021 Financial Results
February 23, 2022
From
Xencor, Inc.
Via
Business Wire
Xencor to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 23, 2022
February 16, 2022
From
Xencor, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Friday
March 04, 2022
On Friday, 368 stocks hit new 52-week lows. Interesting Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was...
Via
Benzinga
Xencor to Present at Upcoming Investor Conferences
February 02, 2022
From
Xencor, Inc.
Via
Business Wire
Earnings Scheduled For February 23, 2022
February 23, 2022
Companies Reporting Before The Bell • Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter. • Plymouth Industrial REIT (NYSE:PLYM)...
Via
Benzinga
Xencor Highlights 2022 Corporate Priorities and Portfolio Milestones
January 11, 2022
From
Xencor, Inc.
Via
Business Wire
Xencor to Present at the H.C. Wainwright Bioconnect Virtual Conference
January 06, 2022
From
Xencor, Inc.
Via
Business Wire
Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting
December 12, 2021
From
Xencor, Inc.
Via
Business Wire
Week In Review: Shanghai's Zenas Acquires CD19 Antibody From Xenco In $480 Million Deal
November 27, 2021
In a $480 million deal, Zenas acquired global rights to a bifunctional antibody from Xencor that targets CD19. Instead of an upfront payment, Zenas will issue a warrant granting Xencor the right to...
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021
December 15, 2021
Upgrades B of A Securities upgraded the previous rating for ONE Gas Inc (NYSE:
Via
Benzinga
Pfizer Sues Former Employee For Stealing Confidential Info On Its Megablockbuster COVID-19 Vaccine
November 24, 2021
Pfizer Inc (NYSE: PFE) has sued its former associate director of clinical statistics in a California court to get a handle on allegedly stolen information. The Company's...
Via
Benzinga
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
Xencor Outlicenses Autoimmune Disease Candidate To Zenas BioPharma
November 22, 2021
Zenas BioPharma has acquired from Xencor Inc (NASDAQ: XNCR) exclusive worldwide rights to develop, manufacture, and commercialize obexelimab. Obexelimab is a...
Via
Benzinga
Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor
November 21, 2021
From
Xencor, Inc.
Via
Business Wire
Xencor to Present at Upcoming Investor Conferences
November 19, 2021
From
Xencor, Inc.
Via
Business Wire
Xencor Presents Updated Data from the Phase 1 Study of Vudalimab, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting
November 12, 2021
From
Xencor, Inc.
Via
Business Wire
Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody Programs and IL-12 Cytokine, XmAb662, at the SITC Annual Meeting
November 12, 2021
From
Xencor, Inc.
Via
Business Wire
Novartis Dumps Another Bispecific Candidate From Xencor Deal
November 09, 2021
Novartis AG (NYSE: NVS) terminated its ex-US rights to the program dubbed vibecotamab, a bispecific targeting CD123 and CD3 for acute myeloid leukemia. The...
Via
Benzinga
Xencor, inc (XNCR) Q3 2021 Earnings Call Transcript
November 08, 2021
XNCR earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.